Lilly to invest $3 billion in China as it seeks approval for orforglipron

Eli Lilly said on March 11, 2026 that it plans to invest $3 billion in China over the next decade, money intended to build production capacity for orforglipron, its experimental once-daily pill for type 2 diabetes and obesity ^[1][2]. The company submitted a marketing application for orforglipron to China's drug regulator at the end of 2025, and the drug is now under review by the National Medical Products Administration ^[1][2].

What the money is for

Lilly said the investment will establish a localized production and supply system for oral solid dosage forms, meaning pills and capsules ^[1][2]. It centers on Lilly's existing plant in Suzhou, along with a network of outside manufacturing partners ^[2]. As part of the announcement, Lilly signed a $200 million deal with contract manufacturer Pharmaron to expand scale "as needed" ^[2].

Over the past two years, Lilly has spent $200 million on the Suzhou plant and created a company innovation center and an incubator for small biotechs there ^[2]. The company says it has invested $6 billion overall in China, from research through commercialization ^[2].

The announcement comes ahead of a summit between U.S. President Donald Trump and China's Xi Jinping this month ^[1]. Lilly is not the only Western health care company expanding there: Haleon and AstraZeneca announced additional China manufacturing investment earlier this year, with AstraZeneca outlining a $15 billion plan ^[1][2]. Not every company is moving in that direction. Bristol Myers Squibb said in September that it had signed an agreement to sell its 60% ownership stake in a China pharmaceutical joint venture that included a Shanghai manufacturing facility ^[1].

Separately, Lilly has been adding U.S. manufacturing capacity, increasing its investment target by $27 billion for a total of $50 billion, as the industry faces pressure from the Trump administration to build supply chains domestically ^[2].

What is known about the pill

Orforglipron is a once-daily oral non-peptide GLP-1 agonist ^[1]. In a late-stage trial, it helped overweight adults without diabetes lose 12.4% of their body weight over 72 weeks at the highest dose ^[1]. In a separate study, it helped patients maintain weight loss when they switched from Lilly's injected GLP-1, sold as Zepbound in the U.S., and from rival Novo Nordisk's Wegovy ^[1].

China has more than 1 billion people and an estimated obesity rate of nearly 9% ^[2]. A decision date from Chinese regulators has not been disclosed, and orforglipron's regulatory status in the United States or any other country has not been reported.

Why it matters for patients

Orforglipron would be a pill rather than an injection, which is a different format from the GLP-1 medicines now sold as Ozempic, Wegovy and Rybelsus (semaglutide) and Mounjaro and Zepbound (tirzepatide). The weight-loss results reported so far come from Lilly's trials of orforglipron and have not been reviewed by U.S. regulators, so how it compares with approved products in everyday use is not yet established.

Lilly's China investment is about making and supplying the drug in China, not about U.S. availability. Nothing in the announcement changes what is currently approved, prescribed, covered by insurance or stocked in U.S. pharmacies. Because the company is also expanding U.S. production, whether the China build-out has any effect on U.S. supply or pricing has not been reported.

The same practical questions that apply to any new GLP-1 also apply here, and the answers are not yet known: when or whether U.S. regulators will act on orforglipron, what it would cost, and whether insurers would cover it. For now, the announced spending is a manufacturing and regulatory step, not a change in treatment options.

What happens next

Lilly's application for orforglipron is with China's drug regulator, and no decision date has been disclosed ^[1][2]. The Trump-Xi summit is expected this month ^[1]. Lilly has not said when production from the expanded Chinese capacity would begin.